

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



VOLUNTARY ANNOUNCEMENT

HARMONI-GI1 RESULTS PUBLISHED AT 2026 ESMO mOS 14.9m vs 12.1m, HR 0.75 (P=0.0031) FOR IVONESCIMAB PLUS CHEMO VS DURVALUMAB PLUS CHEMO IN 1L ADVANCED BTC

This announcement is made by Akeso, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the “**Board**”) announces that HARMONi-GI1/AK112–309 was selected as a Late-Breaking Abstract (LBA) for oral presentation, presented by Principal investigator Professor Jian Zhou, Academician of the Chinese Academy of Sciences, President of Zhongshan Hospital, Fudan University.

HARMONi-GI1/AK112–309 (CTR20243164) is a randomized, controlled, double-blind, registrational Phase III trial to evaluate ivonescimab plus chemo versus durvalumab plus chemo as first-line treatment for advanced biliary tract cancer (BTC). This study enrolled a total of 682 participants. In August 2026, the Independent Data Monitoring Committee (IDMC) declared that the pre-specified interim analysis of this study met its primary endpoint of overall survival (OS), achieving statistically significant and clinically meaningful positive results; the study met all key secondary endpoints of progression-free survival (PFS) and objective response rate (ORR). The results showed:

Among ITT population,

- The median overall survival (mOS) was 14.9 months in the ivonescimab group versus 12.1 months in the durvalumab group, with OS HR 0.75 (95% CI: 0.61–0.92), corresponding to a 25% reduction in the risk of death (P=0.0031)
- The 12-month OS rate was 59.7% in the ivonescimab group versus 50.7% in the durvalumab group. The 18-month OS rate was 44.0% in the ivonescimab group versus 32.5% in the durvalumab group

- The median PFS (mPFS) was 8.4 months in the ivonescimab group versus 5.8 months in the durvalumab group, with PFS HR 0.61, representing a 39% reduction in the risk of disease progression or death ($P < 0.0001$)
- The ORR in ivonescimab group was 53.8%, compared with 32.5% of the durvalumab group, an absolute difference of 21.3 percentage points ($P < 0.0001$)

Ivonescimab demonstrated a favorable safety profile, accompanied by longer treatment exposure. The most common adverse events of any grade and of grade 3/4 were hematologic toxicities; no new safety signals were identified.

Biliary tract cancer is a highly heterogeneous malignancy arising from the bile ducts and gallbladder and carries a poor prognosis. PD-1/L1 inhibitor plus chemotherapy is the established international first-line treatment for advanced biliary tract cancer, yet the overall survival benefit remains limited.

The breakthrough data from HARMONi-GI1 strongly support the potential of ivonescimab plus chemotherapy as a new standard of care for first-line advanced BTC. Furthermore, as the first Phase III study to achieve a positive result in gastrointestinal cancers following multiple Phase III successes in lung cancer, HARMONi-GI1 marks the expansion of ivonescimab's breakthrough clinical value from lung cancer into a broader range of solid tumors. Ivonescimab plus chemotherapy for first-line BTC has been proposed for Priority Review designation by China's National Medical Products Administration (NMPA).

In parallel, Akeso's global partner for ivonescimab, Summit Therapeutics, has entered into a collaboration with the ECOG-ACRIN Cancer Research Group and has initiated the global multicenter registrational Phase II/III EA2251 study evaluating ivonescimab plus chemotherapy versus pembrolizumab or durvalumab plus chemotherapy in first-line advanced biliary tract cancer.

ABOUT HARMONi-GI1/AK112-309

HARMONi-GI1/AK112-309 (CTR20243164) is a randomized, controlled, double-blind, registrational Phase III trial to evaluate ivonescimab plus chemo versus durvalumab plus chemo as first-line treatment for advanced BTC, with primary endpoint of OS. The primary endpoint is overall survival (OS), and the key secondary endpoints are progression-free survival (PFS) and objective response rate (ORR) as assessed by investigators per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). HARMONi-GI1 enrolled 682 participants.

ABOUT 依達方® (IVONESCIMAB, PD-1/VEGF)

依達方® (ivonescimab) is a novel global first-in-class PD-1/VEGF bi-specific immunotherapy drug independently developed by the Company. On May 24, 2024, 依達方® was granted marketing approval by NMPA for the treatment of EGFR mutated locally advanced or metastatic non-squamous NSCLC patients who have progressed after EGFR TKI treatment. On April 25, 2025, the sNDA of ivonescimab as first-line treatment for locally advanced or metastatic NSCLC with PD-L1 positive expression was approved. On August 12, 2026, the sNDA of ivonescimab as first-line treatment for advanced squamous NSCLC was approved. The Company is conducting over 60 Phase II/III clinical trials of ivonescimab

covering over 40 indications including lung cancer, biliary tract cancer, head and neck squamous carcinoma, triple negative breast cancer, colorectal cancer, pancreatic cancer and urothelial cancer. Currently, more than 18 Phase III clinical studies globally of ivonescimab are ongoing, 7 of which are international multicenter registrational Phase III clinical trials.

By order of the Board

Akeso, Inc.

Dr. XIA Yu

Chairwoman and executive Director

Hong Kong, October 26, 2026

As at the date of this announcement, the Board comprises Dr. XIA Yu as chairwoman and executive director, Dr. LI Baiyong, Dr. WANG Zhongmin Maxwell and Dr. ZHANG Peng as executive directors, Mr. XIE Ronggang as non-executive director, and Dr. ZENG Junwen, Dr. XU Yan and Mr. TAN Bo as independent non-executive directors.